A Study of HS-10529 in KRAS G12D Patients With Advanced Solid Tumors
NCT ID: NCT06963398
Last Updated: 2025-05-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE1
520 participants
INTERVENTIONAL
2025-05-15
2029-08-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase I Study of HRS-6093 in Participants With Advanced Solid Tumors Harboring KRAS G12D Mutations
NCT07134998
Phase 1/2 Study of HS-10370 in Patients with Advanced Solid Tumors
NCT05367778
A Study of HS-20110 in Participants With Advanced Solid Tumors
NCT06892379
A Study of HS-20122 in Patients With Advanced Solid Tumors
NCT06927570
A Phase I Clinical Study of HRS-7058 in Patients With Advanced Malignant Tumour
NCT06383871
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HS-10529
HS-10529
Participants in all subjucts will receive HS-10529
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HS-10529
Participants in all subjucts will receive HS-10529
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients of advanced solid tumor，who have progressed on or intolerant to standard therapy.
* With measurable lesion according to RECIST 1.1.
* Agree to provide fresh or archival tumor tissue.
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0\~1.
Exclusion Criteria
* Uncontrolled pleural, ascites or pericardial effusion.
* Known and untreated, or active central nervous system metastases.
* History of other primary malignant tumors.
* Serious, uncontrolled, or active comorbidities.
* Refractory nausea, vomiting, or chronic gastrointestinal diseases, or inability to swallow oral medications.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Jiangsu Hansoh Pharmaceutical Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HS-10529-101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.